Lin Xiao-Qing, Li A-Li, Zhang Mei-Xian, Lv Li, Chen Yan, Chen He-Dan, Tung Tao-Hsin, Zhu Jian-Sheng
Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai 317000, China.
Evidence-Based Medicine Center, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai 317000, China.
Vaccines (Basel). 2022 Oct 6;10(10):1665. doi: 10.3390/vaccines10101665.
Vaccination is an important measure to control the spread of COVID-19 among elderly high-risk groups; however, the propensity to receive COVID-19 vaccine boosters has not been evaluated in these populations. Here, we aimed to investigate the willingness to receive a COVID-19 vaccine booster among the elderly chronic disease population in Taizhou, China. A cross-sectional, hospital-based survey was conducted in the outpatient department of a tertiary care hospital between 6 July and 11 August 2021 in Taizhou, China, and the data were uploaded to Wen-Juan-Xing, one of the largest online platforms used to collect survey data in China. The targeted population was non-oncology chronic disease patients aged 60 years and above. The minimum sample size was 229, determined by the G*Power software (v3.1.9.2, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany). A total of 254 patients with valid data were enrolled in this study, with a response rate of 82.5% (254/308). Chi-square tests and one-way binary regression were used to compare the proportions and the degree of influence of categorical factors. The magnitude of the effect for the comparisons was measured by Gramer’s V. A multivariate binary logistic regression model was used to correct for confounders and to identify factors. All data were analyzed using SPSS v24.0 (IBM Corporation, Armonk, NY, USA). A total of 198 respondents (77.9%) were willing to receive a COVID-19 vaccine booster dose, and 77.6% of respondents were willing to receive the primary dose. Age < 70 years (OR 2.82), stable disease control (OR 2.79), confidence in the effectiveness of the COVID-19 vaccine (OR 3.11), and vaccine recipient (OR 5.02) were significantly associated with the willingness to receive a COVID-19 vaccine booster dose. Promoting primary dose vaccination is essential for advancing booster vaccination, and it is important to focus on elderly patients’ confidence in the vaccine, in addition to strengthening health management and promoting disease stability. Follow-up studies should focus on elderly patients who belong to specific disease groups.
接种疫苗是控制新冠病毒在老年高危人群中传播的一项重要措施；然而，尚未对这些人群接种新冠病毒疫苗加强针的倾向进行评估。在此，我们旨在调查中国泰州老年慢性病患者群体接种新冠病毒疫苗加强针的意愿。2021年7月6日至8月11日在中国泰州一家三级医院的门诊部进行了一项基于医院的横断面调查，数据上传至问卷星，这是中国最大的用于收集调查数据的在线平台之一。目标人群为60岁及以上的非肿瘤慢性病患者。最小样本量由G*Power软件（v3.1.9.2，德国杜塞尔多夫海因里希 - 海涅大学）确定为229。本研究共纳入254例有有效数据的患者，应答率为82.5%（254/308）。采用卡方检验和单向二元回归比较分类因素的比例和影响程度。比较的效应大小用克莱默V系数衡量。使用多变量二元逻辑回归模型校正混杂因素并识别相关因素。所有数据均使用SPSS v24.0（美国纽约州阿蒙克市IBM公司）进行分析。共有198名受访者（77.9%）愿意接种新冠病毒疫苗加强针，77.6%的受访者愿意接种首剂疫苗。年龄<70岁（比值比2.82）、疾病控制稳定（比值比2.79）、对新冠病毒疫苗有效性的信心（比值比3.11）以及曾接种过疫苗（比值比5.02）与接种新冠病毒疫苗加强针的意愿显著相关。推广首剂疫苗接种对于推进加强针接种至关重要，除了加强健康管理和促进疾病稳定外，关注老年患者对疫苗的信心也很重要。后续研究应关注属于特定疾病群体的老年患者。
